Robert Chen

Xuzhou Medical College — China

Medicine · Health Sciences

39h-index8.5kcitations172works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(149), Chronic Lymphocytic Leukemia Research(51), CAR-T cell therapy research(37), Lung Cancer Treatments and Mutations(36), Viral-associated cancers and disorders(28)

Publications172 total

Antibody targeting of C1q and its receptors (gC1qR and cC1qR) to inhibit tumor proliferation in human cancers 3943
The Journal of Immunology·2025Open Access
LB1116 Factors influencing patient follow-up after skin cancer removal: A retrospective cohort study
Journal of Investigative Dermatology·2025Open Access
Development of linear IgA bullous dermatosis in a patient during an exacerbation of psoriasis
Annales de Dermatologie et de Vénéréologie·2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
HemaSphere·2025· 2 citedOpen Access
PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Blood·2024· 3 citedOpen Access
1343 A CB21-targeted T cell engager is a promising therapeutic for the treatment of colorectal cancer
Regular and Young Investigator Award Abstracts·2024Open Access
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2024· 4 cited
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)
HemaSphere·2023· 1 citedOpen Access
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
Haematologica·2023· 16 citedOpen Access
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
Blood·2023· 36 citedOpen Access
Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Data from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Data from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Supplemental Figure 3 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Supplemental Figure 2 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
Supplemental Figure 4 from CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Ajay K. Gopal(13), Stephen J. Forman(13), Leslie Popplewell(11), Ranjana H. Advani(11), Radhakrishnan Ramchandren(10), Craig H. Moskowitz(10), Anas Younes(8), Scott E. Smith(8), Stephen M. Ansell(8), Andres Forero‐Torres(8), Philippe Armand(8), Alex F. Herrera(8), Auayporn Nademanee(8), Joseph M. Connors(7), Joo Y. Song(7), Joycelynne Palmer(7), Jasmine Zain(7), Joseph D. Rosenblatt(6), Kerry J. Savage(6), Nancy L. Bartlett(6)